- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656430
ICBT for Psychological Symptoms Related to the COVID-19 Pandemic Remaining After Societal Opening (PCC)
Internet-based Cognitive Behavioral Therapy for Psychological Symptoms Related to the COVID-19 Pandemic Remaining After Societal Opening
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized controlled trial about the effects of ICBT regarding psychological symptoms related to the COVID-19 pandemic and its consequences remaining after societal opening. Primary outcome measures are depression symptoms (measured with Beck Depression Inventory-II) and anxiety symptoms (measured with Generalized Anxiety Disorder-7). Other outcome measures used will for example be about stress symptoms, sleep problems, post traumatic stress symptoms and quality of life.
Because of uncertainties about the psychological effects of COVID-19 pandemic, a transproblematic individually tailored treatment will be used that has been tested in several previous trials and adapted for addressing problems related to the pandemic and its consequences. The study (nor the recruitment within it) has not a focus on whether people have or have not been infected by the COVID-19 virus.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Östergötland County
-
Linköping, Östergötland County, Sweden, 58183
- Department of Behavioral Sciences and Learning, Linköping University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Experience mental health problems related to the COVID-19 pandemic and/or its consecuences, which are still experienced as a problem (when the pandemic is not considered as dangerous to the society)
- 18 years or older
- Adequate ability to speak, read and write in Swedish
- Having access to the internet and a smartphone, computer or other device
Exclusion Criteria:
- Severe psychiatric or somatic issues that makes participation harder or impossible (which can include the diagnosis postcovid)
- Ongoing addiction
- Acute suicidality
- Other ongoing psychological treatment
- Recent (within the past 3 months) changes in the dose of psychotropic medication or planned change during the treatment weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment group
Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
|
Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation.
The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
|
|
No Intervention: Control group
The control group is a wait-list control condition.
Participants are instructed to wait.
After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Becks Depression Inventory-II
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of depressive symptoms.
Range for the total sum is between 0 and 63 with a higher score indicating a higher level of depressive symptoms.
Clinical ranges for minimal, mild, moderate and severe major depressive disorder are considered to be 0-13, 13-19, 20-28, and 29-63 points respectively.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Generalized Anxiety Disorder-7
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of anxiety symptoms and worry.
When summing the points of the seven first questions, the scores are interpreted as mild, moderate and severe anxiety symptoms at 5-10, 11-15 and above 15 respectively.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percieved Stress Scale-14
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A questionnaire that aims to measure symptoms of stress.
I contains 14 items that are scored on a range betewwn 0 (never) to 4 (very often).
The total score range is between 0-56 and a higher score reflects higher levels of perceived stress.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Insonnia Severity Index
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of insomnia severity and symptoms of disordered sleep.
Norm score ranges include low likelihood of sleep problems (0 to 7 points), some sleep problems (8 to 14 points), moderate sleep problems (15 to 21 points), severe sleep problems (22 to 28 points).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Short Health Anxiety Inventory-14
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of health anxiety, short version, with 14 items which are answered on a scale 0-3.
This gives a total scare range of 0-42, where 0-14 indicate low probability of health anxiety, 15-17 is a grey zone and points over 18 indicates high probability for health anxiety.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Alcohol Use Disorder Identification Test
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A 10-item screening tool to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
10 items and scores ranging from 0-40 with higher scores indicating a higher level of alcohol use.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Karolinska Exhaustion Disorder Scale 9
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A questionnaire aiming to measure fatigue and exhaustion.
Maximum score is 54 and people scoring higher than 18 points are considered as being at risk for exhaustion syndrome.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Impact of Event Scale-6
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A short version of Impact of Event Scale-R (IES-R), which assesses subjective distress caused by potentially traumatic events.
It yields a total score between 0-24 with a higher score indicating more severe distress caused by the traumatic events.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
UCLA loneliness scale 3
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A short version of the UCLA loneliness scale, aiming to measure with three questions, for example "How often do you feel left out?" and are answered on a scale ranging from 1 (hardly ever) to 3 (often).
People who gets the score 3-5 have been grouped as not lonely, while score 6-9 has been grouped as lonely.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Brunnsviken Brief Quality of Life Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of quality of life with a total score ranging from 0 to 96 with a higher score indicating a higher quality of life.
The scores of each of the six primary questions regarding perceived quality of life within an area of life are multiplied with the score of an item measuring the perceived importance of the area in question.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
The Cognitive Failures Questionnaire
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
The measure contains 25 questions and are aiming to measure the experience of the frequency of misstakes one does in the every day life because of problems with attention, memory, and emotion regulation.
Maximum score are 100, where higher score mirrors experienced problems to a greater extent.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
InCharge Financial Distress/Financial Well-Being Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A measure aiming to measure distress related to the individual's economic situation.
It contains of eight questions where the respondent gets to answer on a scale from 1 to 10.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knowledge test
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Knowledge test about cognitive behavior therapy and how strategies in cognitive behavior therapy can be applied in every day situations.
It consists of 16 questions and the respondent gets three answer options while one of the alternatives are correct.
The respondent also gets to answer how confident he/she is about the answer (I'm guessing, I'm pretty certain, I'm quite certain).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerhard Andersson, PhD, Linkoeping University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PostCoronaCope
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.